| Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration (NCT02339987) | Saint John's Cancer Institute | 2014-11-01 |
| Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (NCT02907827) | Universitair Ziekenhuis Brussel | 2014-11-01 |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma (NCT02302339) | Celldex Therapeutics | 2014-11-01 |
| PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (NCT02307630) | Memorial Sloan Kettering Cancer Center | 2014-11-01 |
| Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors (NCT02285101) | Bio-Cancer Treatment International Limited | 2014-11-01 |
| RTA 408 Capsules in Patients With Melanoma - REVEAL (NCT02259231) | Biogen | 2014-10-31 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (NCT03176485) | University of Arizona | 2014-10-17 |
| A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) (NCT02156804) | Bristol-Myers Squibb | 2014-10-07 |
| Nevus Doctor Clinical Decision Support (NCT02012751) | University Hospital of North Norway | 2014-10-01 |
| Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (NCT01972347) | Melanoma Institute Australia | 2014-10-01 |
| A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma (NCT02400385) | California Pacific Medical Center Research Institute | 2014-10-01 |
| Biomarker Correlates of Hypoxia in Metastatic Melanoma (NCT02061007) | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-01 |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (NCT02054104) | National Cancer Institute (NCI) | 2014-09-03 |
| Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma (NCT02251314) | University Health Network, Toronto | 2014-09-01 |
| Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients (NCT02143050) | University of Louisville | 2014-09-01 |
| A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) (NCT02155322) | Merck Sharp & Dohme LLC | 2014-08-19 |
| CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases (NCT02058953) | University of Pittsburgh | 2014-08-12 |
| FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA) (NCT02425475) | University Hospital Tuebingen | 2014-08-01 |
| Treatment of Advanced Melanoma With MK-3475 and Peginterferon (NCT02112032) | Hassane M. Zarour, MD | 2014-07-24 |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (NCT02159066) | Pfizer | 2014-07-23 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody (NCT02159443) | St. Jude Children's Research Hospital | 2014-07-15 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) (NCT02180061) | Merck Sharp & Dohme LLC | 2014-07-15 |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive (NCT02153905) | National Cancer Institute (NCI) | 2014-07-03 |
| A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care (NCT02279004) | Dana-Farber Cancer Institute | 2014-07-03 |
| A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma (NCT02138292) | University of Texas Southwestern Medical Center | 2014-07-01 |
| Infrared Lymphangiography as a Method of Sentinel Node Identification (NCT02057393) | Milton S. Hershey Medical Center | 2014-06-01 |
| A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (NCT02130466) | Merck Sharp & Dohme LLC | 2014-05-29 |
| Fluorescence Surgery for Sentinel Node Identification in Melanoma (NCT02142244) | Barretos Cancer Hospital | 2014-05-01 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (NCT02126579) | Craig L Slingluff, Jr | 2014-05-01 |
| Validation of MMS Test for Cancer Monitoring (NCT02113683) | MedInnovation GmbH | 2014-05-01 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec (NCT02014441) | Amgen | 2014-04-07 |
| GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (NCT02115139) | Grupo Español Multidisciplinar de Melanoma | 2014-04-04 |
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (NCT01959633) | Fondazione Melanoma Onlus | 2014-04-03 |
| Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma (NCT02190838) | N.N. Petrov National Medical Research Center of Oncology | 2014-04-01 |
| Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children (NCT02129049) | University of Washington | 2014-04-01 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma (NCT01970358) | Patrick Ott, MD, PhD | 2014-04-01 |
| A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (NCT01984255) | University of Texas Southwestern Medical Center | 2014-04-01 |
| A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma (NCT02068079) | Duke University | 2014-04-01 |
| Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma (NCT02083354) | Novartis Pharmaceuticals | 2014-03-18 |
| Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (NCT02089685) | Merck Sharp & Dohme LLC | 2014-03-17 |
| MK-3475 in Melanoma and NSCLC Patients With Brain Metastases (NCT02085070) | Yale University | 2014-03-01 |
| A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (NCT02107963) | National Cancer Institute (NCI) | 2014-02-28 |
| Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT02111863) | National Cancer Institute (NCI) | 2014-02-21 |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (NCT02111850) | National Cancer Institute (NCI) | 2014-02-07 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. (NCT02012231) | Fore Biotherapeutics | 2014-02-01 |
| Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma (NCT02316795) | Washington University School of Medicine | 2014-02-01 |
| A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma (NCT01888081) | Virogen Biotechnology Inc. | 2014-02-01 |
| HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma (NCT03435302) | Peking University Cancer Hospital & Institute | 2014-02-01 |
| Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R (NCT02045368) | IGF Oncology, LLC | 2014-01-28 |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (NCT02032810) | H. Lee Moffitt Cancer Center and Research Institute | 2014-01-07 |
| Ensuring Communication in Hospice by Oncology Study (ECHO) (NCT02069769) | Massachusetts General Hospital | 2014-01-01 |
| MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (NCT01973608) | EMD Serono | 2014-01-01 |
| The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors (NCT04583605) | Central Hospital, Nancy, France | 2014-01-01 |
| Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone (NCT02027961) | MedImmune LLC | 2013-12-20 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (NCT01962103) | Celgene | 2013-12-04 |
| Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma (NCT02023710) | Peking University Cancer Hospital & Institute | 2013-12-01 |
| Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (NCT01990859) | Bristol-Myers Squibb | 2013-12-01 |
| IVAC MUTANOME Phase I Clinical Trial (NCT02035956) | BioNTech RNA Pharmaceuticals GmbH | 2013-12-01 |
| A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma (NCT01986712) | St. Luke's Hospital and Health Network, Pennsylvania | 2013-12-01 |
| A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (NCT02014116) | Eli Lilly and Company | 2013-11-26 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib (NCT02314143) | GlaxoSmithKline | 2013-11-13 |
| BioMEL- Diagnostic and Prognostic Factors in Melanoma. (NCT05446155) | Region Skane | 2013-11-04 |
| LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (NCT01820364) | Array BioPharma | 2013-11-01 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (NCT01986426) | Lytix Biopharma AS | 2013-11-01 |
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (NCT01984892) | Nina Bhardwaj | 2013-11-01 |
| Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma (NCT02828345) | Abramson Cancer Center at Penn Medicine | 2013-11-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |
| PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma (NCT02492815) | Bristol-Myers Squibb | 2013-10-31 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer (NCT01967823) | National Cancer Institute (NCI) | 2013-10-24 |
| Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer (NCT01896778) | Roswell Park Cancer Institute | 2013-10-04 |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (NCT01943422) | John Kirkwood | 2013-10-01 |
| T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma (NCT01946373) | Karolinska University Hospital | 2013-10-01 |
| Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (NCT01876641) | Mohammed M Milhem | 2013-10-01 |
| Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (NCT01909453) | Pfizer | 2013-09-12 |
| Trametinib With GSK2141795 in BRAF Wild-type Melanoma (NCT01941927) | Adil Daud | 2013-09-10 |
| The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma (NCT01942993) | Philip Friedlander | 2013-09-01 |
| Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study (NCT01960829) | Peking University Cancer Hospital & Institute | 2013-09-01 |
| Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (NCT01866319) | Merck Sharp & Dohme LLC | 2013-08-28 |
| Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors (NCT01639911) | University of Illinois at Chicago | 2013-08-14 |
| Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. (NCT02600143) | University Medical Center Groningen | 2013-08-01 |
| Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (NCT01495988) | Melanoma Research Foundation Breakthrough Consortium | 2013-08-01 |
| Engagement of Patients With Advanced Cancer (NCT02966509) | Stanford University | 2013-08-01 |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor (NCT01603212) | M.D. Anderson Cancer Center | 2013-07-18 |
| Tissue Procurement Substudy for Participants in Study CP-MGA271-01 (NCT01918930) | MacroGenics | 2013-07-01 |
| A Study of rSIFN-co in Subjects With Advanced Solid Tumors (NCT02387307) | Sichuan Huiyang Life Science and Technology Corporation | 2013-07-01 |
| Spanish Registry of Mohs Surgery (NCT02310503) | Fundación Academia Española de Dermatología | 2013-07-01 |
| In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma (NCT02759536) | The Third Xiangya Hospital of Central South University | 2013-07-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative (NCT01916135) | Memorial Sloan Kettering Cancer Center | 2013-07-01 |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation (NCT01894672) | Memorial Sloan Kettering Cancer Center | 2013-07-01 |
| The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases (NCT01785316) | Vastra Gotaland Region | 2013-06-15 |
| A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (NCT01897116) | Abramson Cancer Center at Penn Medicine | 2013-06-01 |
| Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) | Northwest Biotherapeutics | 2013-06-01 |
| Dendritic Cell Activating Scaffold in Melanoma (NCT01753089) | Dana-Farber Cancer Institute | 2013-06-01 |
| Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma (NCT01863108) | University Hospital, Grenoble | 2013-06-01 |